ZoetisZTSEarnings & Financial Report
Zoetis Inc. (/zō-EH-tis/) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries.
ZTS Q4 2025 Key Financial Metrics
Revenue
$2.4B
Gross Profit
$1.7B
Operating Profit
N/A
Net Profit
$603.0M
Gross Margin
70.2%
Operating Margin
N/A
Net Margin
25.3%
YoY Growth
3.0%
EPS
$1.37
Financial Flow
Zoetis Q4 2025 Financial Summary
Zoetis reported revenue of $2.4B for Q4 2025, with a net profit of $603.0M (25.3% margin). Cost of goods sold was $712.0M, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $2.4B |
|---|---|
| Net Profit | $603.0M |
| Gross Margin | 70.2% |
| Operating Margin | N/A |
| Report Period | Q4 2025 |
Zoetis Annual Revenue by Year
Zoetis annual revenue history includes year-by-year totals (for example, 2025 revenue was $9.5B).
| Year | Annual Revenue |
|---|---|
| 2025 | $9.5B |
| 2024 | $9.3B |
| 2023 | $8.5B |
| 2022 | $8.1B |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.19B | $2.36B | $2.39B | $2.32B | $2.22B | $2.46B | $2.40B | $2.39B |
| YoY Growth | 9.5% | 8.3% | 11.0% | 4.7% | 1.4% | 4.2% | 0.5% | 3.0% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $14.35B | $14.16B | $14.36B | $14.24B | $14.10B | $14.48B | $15.16B | $15.47B |
| Liabilities | $9.30B | $9.21B | $9.12B | $9.47B | $9.44B | $9.50B | $9.76B | $12.14B |
| Equity | $5.06B | $4.97B | $5.23B | $4.77B | $4.66B | $4.98B | $5.40B | $3.33B |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $595.0M | $502.0M | $951.0M | $905.0M | $587.0M | $486.0M | $938.0M | $893.0M |
Other Health Care Companies
BMY
Bristol Myers Squibb
Revenue
$12.5B
Net Profit
$1.1B
JNJ
Johnson & Johnson
Revenue
$24.6B
Net Profit
$5.1B
LLY
Lilly (Eli)
Revenue
$19.3B
Net Profit
$6.6B
MRK
Merck & Co.
Revenue
$17.3B
Net Profit
$5.8B
PFE
Pfizer
Revenue
$16.7B
Net Profit
$3.5B
VTRS
Viatris
Revenue
$3.7B
Net Profit
N/A
ABT
Abbott Laboratories
Revenue
$11.4B
Net Profit
$1.6B
ABBV
AbbVie
Revenue
$15.8B
Net Profit
$186.0M
A
Agilent Technologies
Revenue
$1.9B
Net Profit
$434.0M
ALGN
Align Technology
Revenue
$995.7M
Net Profit
$56.8M